Cars.com
CARS
Hutchmed (China)
HCM
Dorian LPG
LPG
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
US Stock MarketDetailed Quotes
EVAX Evaxion Biotech
- 1.960
- +0.130+7.10%
Trading Mar 11 10:41 ET
12.28MMarket Cap-0.14P/E (TTM)
1.989High1.811Low24.40KVolume1.800Open1.830Pre Close46.17KTurnover0.53%Turnover RatioLossP/E (Static)6.27MShares22.04852wk High163.33P/B9.05MFloat Cap1.70052wk Low--Dividend TTM4.62MShs Float1252.000Historical High--Div YieldTTM9.74%Amplitude1.700Historical Low1.892Avg Price1Lot Size
Evaxion Biotech Stock Forum
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; F...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, I...
Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package
Tuesday, 25th February at 8:00 am
Originally planned as a two-year study, the trial has been extended by an additional year to collect three-year clinical outcome data
The additional third year of EVX-01 dosing may provide further insights into potential enhanced treatment effects and durability of induced immune response
The trial already yielded convin...
Evaxion Extends Phase 2 Trial With Personalized Cancer Vaccine Evx-01 to Further Enhance Clinical Data Package
Financial Turnaround: Evaxion Secures Future with $17M Raise, Dodges Delisting
Nasdaq Confirms Evaxion Is Fully Compliant, Withdraws Delisting Determination
No comment yet